author-photo

Patricia McCoon

AstraZeneca

24

Papers

668

Citations

Citation Trend

Filter By

Papers (18) Sort By

Journal Conference Others

T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Exposure-response (E-R) efficacy and safety (E-S) analyses of tremelimumab as monotherapy or in combination with durvalumab in patients (pts) with unresectable hepatocellular carcinoma (uHCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
STAT3 antisense oligonucleotide remodels the suppressive tumor microenvironment to enhance immune activation in combination with anti-PD-L1

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (8)
Abstract LB-105: Plasma exposure-target engagement biomarker analysis for danvatirsen after multiple dosing schedules and route of administrations in patients with advanced solid tumors

2020
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 3215: STAT3 antisense oligonucleotide (ASO) reverses immunosuppression and enhances cytotoxic cell function to enhance PDL1 blockade

2019 Immunology
Show All
- Source
- Cite
- Save
Citations (0)
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells

2018 Journal of Clinical Investigation
Show All
- Source
- Cite
- Save
Citations (39)
1044OA phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (24)
Abstract 2641: AZD4635 A2A receptor occupancy in cynomolgus monkey using PET and its application to an oncology clinical development program

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
1135OPhase 1b/2 Study (SCORES) assessing safety, tolerability, and preliminary anti-tumor activity of durvalumab plus AZD9150 or AZD5069 in patients with advanced solid malignancies and squamous cell carcinoma of the head and neck (SCCHN)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (12)
A phase 1b study (SCORES) assessing safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of durvalumab combined with AZD9150 or AZD5069 in patients with advanced solid malignancies and SCCHN

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (6)